Glycated Albumin

CPT: 82985
Print Share

Expected Turnaround Time

2 - 4 days

Related Documents

For more information, please view the literature below.

Glycated Albumin: A Better Biomarker for Short-term Glycemic Control

Specimen Requirements




1 mL

Minimum Volume

0.2 mL


Gel-barrier tube


Separate serum from cells within 45 minutes of collection. Transfer to a plastic tranport tube before shipping.

Storage Instructions


Stability Requirements



Room temperature

4 days


14 days


14 days

Freeze/thaw cycles

Stable x3

Causes for Rejection

Plasma specimen

Test Details


This test is intended to be used for the quantitative measurement of glycated albumin in human serum. The measurement of glycated albumin is useful for the intermediate term (preceding 2-3 weeks) monitoring of glycemic control in patients with diabetes. HbA1c has limitations in which glycemic control may not be accurately reflected. In these conditions (such as hemolytic anemia, blood transfusion, variant hemoglobin, chronic renal failure, liver cirrhosis, iron deficiency anemia, pregnancy), GA measurement may be more appropriate over HbA1c.1



Additional Information

To avoid the complications of diabetes mellitus, strict glycemic control is needed. Because glycated albumin (GA) reflects the state of glycemic control during the past two weeks to one month,2 it is useful for the intermediate term (preceding two to three weeks) monitoring of glycemic control in patients with diabetes.3 For evidence regarding GA and diabetes complications, a case cohort study for DCCT/EDIC study showed that GA is a risk factor equivalent to HbA1c in the microvascular complications of diabetes.4 The ARIC study that followed nearly 11,104 patients for 20 years showed that GA, like HbA1c, is related to total mortality and heart disease.5

Peer-reviewed literature supports the use of glycated albumin (GA) as a good marker of glycemic control based on clinical outcomes, for microvascular complications, macrovascular complications, diabetes risk, prognosis in hemodialysis patients and predicting pregnancy outcomes. GA has been shown to be useful for the intermediate term monitoring of glycemic control in patients with diabetes. For microvascular complications, studies involving collectively more than 11,000 subjects in the USA4,6 and in China,7 followed for 5 to 20 years revealed that GA is associated with the onset and progression of diabetic microvascular complications. For macrovascular complications, studies in the USA,5 Japan,8 Korea,9,10 and China11 involving collectively more than 11,000 subjects revealed that GA is associated with vascular outcomes, atheroscclerosis, poor prognosis and mortality.


1. Koga M, Kasayama S. Clinical impact of glycated albumin as another glycemic control marker. Endocr J. 2010;57(9):751-76220724796
2. Tahara Y, Shima K. Kinetics of HbA1c, glycated albumin, and fructosamine and analysis of their weight functions against preceding plasma glucose level. Diabetes Care. 1995 Apr;18(4):440-447.7497851
3. Desouza CV, Rosenstock J, Zhou R, Holcomb RG, Fonseca VA. Glycated albumin at 4 weeks correlates with A1c levels at 12 weeks and reflects short-term glucose fluctuations. Endocr Pract. 2015 Nov;21(11):1195-1203.26214108
4. Nathan DM, McGee P, Steffes MW, Lachin JM, DCCT/EDIC Research Group. Relationship of glycated albumin to blood glucose and HbA1c values and to retinopathy, nephropathy, and cardiovascular outcomes in the DCCT/EDIC study. Diabetes. 2014 Jan;63(1):282-290.23990364
5. Selvin E, Rawlings AM, Lutsey PL, et al. Fructosamine and Glycated Albumin and the Risk of Cardiovascular Outcomes and Death. Circulation. 2015 Jul 28;132(4):269-277.26022911
6. Selvin E, Rawlings AM, Grams M, et al. Fructosamine and glycated albumin for risk stratification and prediction of incident diabetes and microvascular complications: a prospective cohort analysis of the Atherosclerosis Risk in Communities (ARIC) study. Lancet Diabetes Endocrinol. 2014 Apr;2(4):279-288.24703046
7. Pan J, Li Q, Zhang L, et al. Serum glycated albumin predicts the progression of diabetic retinopathy--a five year retrospective longitudinal study. J Diabetes Complications. Nov-Dec 2014;28(6):772-778.25073934
8. Mukai N, Ninomiya T, Hata J, et al. Association of hemoglobin A1c and glycated albumin with carotid atherosclerosis in community-dwelling Japanese subjects: the Hisayama Study. Cardiovasc Diabetol. 2015 Jun 24;14:84.26099223
9. Song SO, Kim, KJ, Lee BW, Kang ES, Cha BS, Lee HC. Serum glycated albumin predicts the progression of carotid arterial atherosclerosis. Atherosclerosis. 2012 Dec;225(2):450-455.23040867
10. Yoon HJ, Lee YH, Kim SR, et al. Glycated albumin and the risk of micro- and macrovascular complications in subjects with type 1 diabetes. Cardiovasc Diabetol. 2015 May 15;14:53.25975731
11. Yang ZK, Shen Y, Shen WF, et al. Elevated glycated albumin and reduced endogenous secretory receptor for advanced glycation endproducts levels in serum predict major adverse cardio-cerebral events in patients with type 2 diabetes and stable coronary artery disease. Int J Cardiol. 2015 Oct 15;197:241-247.26142969


Order Code Order Code Name Order Loinc Result Code Result Code Name UofM Result LOINC
123030 Glycated Albumin 1758-2 123033 Glycated Alb % % 13873-5

For Providers

Please login to order a test

Order a Test

© 2021 Laboratory Corporation of America® Holdings and Lexi-Comp Inc. All Rights Reserved.

CPT Statement/Profile Statement

The LOINC® codes are copyright © 1994-2021, Regenstrief Institute, Inc. and the Logical Observation Identifiers Names and Codes (LOINC) Committee. Permission is granted in perpetuity, without payment of license fees or royalties, to use, copy, or distribute the LOINC® codes for any commercial or non-commercial purpose, subject to the terms under the license agreement found at Additional information regarding LOINC® codes can be found at, including the LOINC Manual, which can be downloaded at